Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.001
Sell
RSI(14)
45.678
Neutral
STOCH(KDJ)(9,3,3)
47.802
Neutral
ATR(14)
0.292
High Vlolatility
CCI(14)
-34.463
Neutral
Williams %R
74.783
Sell
TRIX(12,20)
-0.001
Sell
StochRSI(14)
0.000
Sell
Immuneering Corp
IMRX4.870USD
-0.350-6.70%
Close 03/30, 16:00（ET）Quotes delayed by 15 min
118.78MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Immuneering Corp
Currency: USD Updated: 2026-03-27Key Insights
Immuneering Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 123 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 17.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Immuneering Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Immuneering Corp Highlights
StrengthsRisks
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.
Undervalued
The company’s latest PE is -3.90, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 31.36M shares, increasing 40.92% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 3.62K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.58.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
17.000
Target Price
+225.67%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-27The current financial score of Immuneering Corp is 6.79, ranking 200 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.48
Operational Efficiency
2.69
Growth Potential
6.75
Shareholder Returns
7.03
Immuneering Corp's Company Valuation
Currency: USD Updated: 2026-03-27The current valuation score of Immuneering Corp is 5.98, ranking 340 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.90, which is -86.14% below the recent high of -0.54 and -76.78% above the recent low of -6.89.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 123/391
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-27The current earnings forecast score of Immuneering Corp is 8.67, ranking 72 out of 391 in the Biotechnology & Medical Research industry. The average price target is 14.00, with a high of 30.00 and a low of 11.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
17.000
Target Price
+242.74%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
548
Total
6
Median
6
Average
Company name
Ratings
Analysts
Immuneering Corp
IMRX
6
CRISPR Therapeutics AG
CRSP
29
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
Beigene Ltd
ONC
24
Intellia Therapeutics Inc
NTLA
24
1
2
3
...
110
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-27The current price momentum score of Immuneering Corp is 6.13, ranking 270 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 5.63 and the support level at 4.48, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
5.170
Sell
MA10
5.027
Sell
MA20
5.155
Sell
MA50
5.042
Sell
MA100
5.731
Sell
MA200
5.398
Sell
Institutional Confidence
Currency: USD Updated: 2026-03-27The current institutional shareholding score of Immuneering Corp is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 48.57%, representing a quarter-over-quarter increase of 27.78%. The largest institutional shareholder is The Vanguard, holding a total of 2.57M shares, representing 3.97% of shares outstanding, with 35.25% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Fidelity Management & Research Company LLC
HBM Partners AG
Zeskind (Benjamin J)
Merrin Investors, L.L.C.
Sanofi SA
Empery Asset Management, L.P.
BlackRock Institutional Trust Company, N.A.
1
2
Risk Assessment
Currency: USD Updated: 2026-03-27The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Immuneering Corp is 4.18, ranking 101 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.47. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.46
VaR
--
240-Day Maximum Drawdown
+55.35%
240-Day Volatility
+111.83%
Return
Best Daily Return
60 days
+23.96%
120 days
+23.96%
5 years
--
Worst Daily Return
60 days
-43.22%
120 days
-43.22%
5 years
--
Sharpe Ratio
60 days
-0.33
120 days
-0.05
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+55.35%
3 years
+90.98%
5 years
--
Return-to-Drawdown Ratio
240 days
+5.14
3 years
-0.13
5 years
--
Skewness
240 days
+1.00
3 years
+0.78
5 years
--
Volatility
Realised Volatility
240 days
+111.83%
5 years
--
Standardised True Range
240 days
+8.98%
5 years
--
Downside Risk-Adjusted Return
120 days
-4.92%
240 days
-4.92%
Maximum Daily Upside Volatility
60 days
+88.82%
Maximum Daily Downside Volatility
60 days
+94.91%
Liquidity
Average Turnover Rate
60 days
+4.21%
120 days
+2.40%
5 years
--
Turnover Deviation
20 days
-58.24%
60 days
-25.05%
120 days
-57.22%
Peer Comparison
Biotechnology & Medical Research
Immuneering Corp
IMRX
6.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Day One Biopharmaceuticals Inc
DAWN
8.26 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.21 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
